<DOC>
	<DOCNO>NCT01497366</DOCNO>
	<brief_summary>This study ass safety efficacy sofosbuvir ( GS-7977 ; PSI-7977 ) combination ribavirin ( RBV ) administer 12 week compare pegylated interferon ( PEG ) /RBV administer 24 week treatment-naive patient Hepatitis C ( HCV ) genotype 2 3 . Efficacy assessed rate sustain viral response ( SVR ) 12 week discontinuation therapy ( SVR12 ) . This non-inferiority study , non-inferiority demonstrate , study allow test superiority .</brief_summary>
	<brief_title>Phase 3 Study Sofosbuvir Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Chronic Genotype 2 3 HCVinfection Naive HCV antiviral treatment ( ) Positive test Screening HBsAg , antihepatitis B core immunoglobulin M antibody ( antiHBc IgM Ab ) , antiHIV Ab History clinically significant chronic liver disease A history consistent decompensated liver disease History current evidence psychiatric illness , immunologic disorder , hemoglobinopathy , pulmonary cardiac disease , seizure disorder anticonvulsant use , poorly control diabetes , cancer , history malignancy , make subject unsuitable study . Participation clinical study within 3 month prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HCV genotype 2 ( GT-2 )</keyword>
	<keyword>HCV genotype 3 ( GT-3 )</keyword>
</DOC>